Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells

Abstract

A hallmark of cancer cells is the ability to proliferate indefinitely. This acquisition of an immortal lifespan usually requires the activation of telomerase, the enzyme that elongates telomeres. Human telomerase is minimally composed of the reverse transcriptase subunit hTERT, and the RNA subunit hTR. While hTR is ubiquitously expressed in human cells, the hTERT subunit is generally transcriptionally repressed in most normal somatic cells, but is illegitimately activated to restore telomerase activity in cancer cells. Indeed, in the thousands of different human tumours assayed, 85% were scored positive for telomerase activity. However, the levels of telomerase activity detected in tumour samples can vary substantially and even some normal somatic cells have been found to have low levels of enzyme activity. As the functional significance of low levels of telomerase activity is unclear, we investigated whether there is a minimum level of telomerase activity required for tumourigenesis. Using mutants of hTERT that induce varying levels of telomerase activity, we show that there does indeed exist a threshold of activity required for the processes of immortalization, transformation and tumourigenesis. Thus, low levels of activity detected in certain somatic cells would not be expected to contribute to tumourigenesis, nor does the mere detection of telomerase in cancer cells necessarily signify an immortal lifespan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Armbruster BN, Banik SS, Guo C, Smith AC, Counter CM . 2001 Mol. Cell. Biol. 21: 7775–7786

  • Banik SSR, Guo C, Smith AC, Margolis SS, Richardson DA, Tirado CA, Counter CM . 2002 Mol. Cell. Biol. (in press)

  • Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE . 1998 Science 279: 349–352

  • Broccoli D, Young JW, de Lange T . 1995 Proc. Natl. Acad. Sci. USA 92: 9082–9086

  • Buchkovich KJ, Greider CW . 1996 Mol. Biol. Cell. 7: 1443–1454

  • Cifone MA, Fidler IJ . 1980 Proc. Natl. Acad. Sci. USA 77: 1039–1043

  • Counter CM, Avilion AA, Le Feuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S . 1992 EMBO J. 11: 1921–1929

  • Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S . 1995 Blood 85: 2315–2320

  • Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA . 1998 Proc. Natl. Acad. Sci. USA 95: 14723–14728

  • Counter CM, Hirte HW, Bacchetti S, Harley CB . 1994 Proc. Natl. Acad. Sci. USA 91: 2900–2904

  • Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA . 2001 Genes Dev. 15: 50–65

  • Farwell DG, Shear KA, Koop JI, Bonnet GA, Matthews CP, Reuther GW, Coltrera MD, McDougall JK, Klingelhutz AJ . 2000 Am. J. Pathol. 156: 1537–1547

  • Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA . 1999 Nature 400: 464–468

  • Halvorsen TL, Leibowitz G, Levine F . 1999 Mol. Cell. Biol. 19: 1864–1870

  • Harle-Bachor C, Boukamp P . 1996 Proc. Natl. Acad. Sci. USA 93: 6476–6481

  • Harley CB, Futcher AB, Greider CW . 1990 Nature 345: 458–460

  • Harley CB . 2002 Oncogene 21: 494–502

  • Harrington L, Zhou W, McPhail T, Oulton R, Yeung DS, Mar V, Bass MB, Robinson MO . 1997 Genes Dev. 11: 3109–3115

  • Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC . 1990 Nature 346: 866–868

  • Kilian A, Bowtell DDL, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA . 1997 Hum. Mol. Genet. 6: 2011–2019

  • Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW . 1994 Science 266: 2011–2015

  • Kim NW, Wu F . 1997 Nucleic Acids Res. 25: 2595–2597

  • Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ . 1998 Nature 396: 84–88

  • Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL . 1998 Nat. Genet. 19: 182–186

  • Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA . 1997 Cell 90: 785–795

  • Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR . 1997 Science 277: 955–959

  • Norrback KF, Dahlenborg K, Carlsson R, Roos G . 1996 Blood 88: 222–229

  • Norrback KF, Roos G . 1997 Eur. J. Cancer 33: 774–780

  • Ouellette MM, Aisner DL, Savre-Train I, Wright WE, Shay JW . 1999 Biochem. Biophys. Res. Commun. 254: 795–803

  • Rich HN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM . 2001 Cancer Res. 61: 3556–3560

  • Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB, Kaelin Jr WG . 1998 Genes Dev. 12: 95–106

  • Shay JW, Bacchetti S . 1997 Eur. J. Cancer 33: 787–791

  • Stewart N, Bacchetti S . 1991 Virology 180: 49–57

  • Vaziri H, Benchimol S . 1998 Curr. Biol. 8: 279–282

  • Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, Ide T, Utakoji T . 1996 Oncogene 13: 433–439

  • Zhu J, Wang H, Bishop JM, Blackburn EH . 1999 Proc. Natl. Acad. Sci. USA 96: 3723–3728

Download references

Acknowledgements

We thank members of the Counter lab for their helpful advice. This work was supported by grants from the National Institute of Health, administered through the National Cancer Institute (CA82481 and CA94184). CM Counter is a Leukemia and Lymphoma Society Scholar. SSR Banik is a Department of Defense Breast Cancer Research Predoctoral Fellow.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christopher M Counter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamad, N., Banik, S. & Counter, C. Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene 21, 7121–7125 (2002). https://doi.org/10.1038/sj.onc.1205860

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205860

Keywords

This article is cited by

Search

Quick links